Activities of Triazole-Echinocandin Combinations against Candida Species in Biofilms and as Planktonic Cells

被引:37
作者
Chatzimoschou, Athanasios [1 ]
Katragkou, Spasia [1 ]
Simitsopoulou, Maria [1 ]
Antachopoulos, Charalampos [1 ]
Georgiadou, Elpiniki [1 ]
Walsh, Thomas J. [2 ,3 ]
Roilides, Emmanuel [1 ,2 ]
机构
[1] Aristotle Univ Thessaloniki, Hippokration Hosp, Infect Dis Lab, Dept Pediat 3, Thessaloniki 54642, Greece
[2] NIH, Immunocompromised Host Sect, Pediat Oncol Branch, Bethesda, MD 20892 USA
[3] Cornell Univ, Transplantat Oncol Infect Dis Program, Div Infect Dis, Weill Cornell Med Coll, New York, NY 10021 USA
关键词
ANTIFUNGAL AGENTS; IN-VITRO; ALBICANS; SUSCEPTIBILITY; EPIDEMIOLOGY; INFECTIONS; SYNERGY; FUTURE;
D O I
10.1128/AAC.00959-10
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Biofilm formation complicates the treatment of various infections caused by Candida species. We investigated the effects of simultaneous or sequential combinations of two triazoles, voriconazole (VRC) and posaconazole (PSC), with two echinocandins, anidulafungin (AND) and caspofungin (CAS), against Candida albicans and Candida parapsilosis biofilms in comparison to their planktonic counterparts. Antifungal activity was assessed by the 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]2H-tetrazolium-5-carboxanilide (XTT) metabolic assay. Antifungal-agent interactions were analyzed by the Bliss independence model in the simultaneous-treatment studies and by analysis of variance (ANOVA) in the sequential-treatment studies. Against C. albicans planktonic cells, the simultaneous combination of PSC (32 to 128 mg/liter) and CAS (0.008 to 0.25 mg/liter) was synergistic; the combinations of PSC (128 to 1,024 mg/liter) with AND (0.03 to 0.5 mg/liter) and VRC (32 to 512 mg/liter) with AND (0.008 to 0.03 mg/liter) were antagonistic. Against C. parapsilosis planktonic cells, the interaction between VRC (32 to 1,024 mg/liter) and CAS (1 to 16 mg/liter) was antagonistic. All simultaneous antifungal combinations demonstrated indifferent interactions against biofilms of both Candida species. Damage to biofilms of both species increased (P < 0.01) in the presence of subinhibitory concentrations of echinocandins (0.008 to 0.064 mg/liter), followed by the addition of PSC (512 mg/liter for C. albicans and 64 to 512 mg/liter for C. parapsilosis) or VRC (256 to 512 mg/liter for C. albicans and 512 mg/liter for C. parapsilosis). Triazole-echinocandin combinations do not appear to produce antagonistic effects against Candida sp. biofilms, while various significant interactions occur with their planktonic counterparts.
引用
收藏
页码:1968 / 1974
页数:7
相关论文
共 37 条
  • [1] Antifungal combinations against Candida albicans biofilms in vitro
    Bachmann, SP
    Ramage, G
    VandeWalle, K
    Patterson, TF
    Wickes, BL
    López-Ribot, JL
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (11) : 3657 - 3659
  • [2] Matrix polymers of Candida biofilms and their possible role in biofilm resistance to antifungal agents
    Baillie, GS
    Douglas, LJ
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (03) : 397 - 403
  • [3] Paradoxical effect of echinocandins across Candida species in vitro:: Evidence for echinocandin-specific and Candida species-related differences
    Chamilos, Georgios
    Lewis, Russell E.
    Albert, Nathaniel
    Kontoyiannis, Dimitrios P.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (06) : 2257 - 2259
  • [4] Biofilm formation by the fungal pathogen Candida albicans:: Development, architecture, and drug resistance
    Chandra, J
    Kuhn, DM
    Mukherjee, PK
    Hoyer, LL
    McCormick, T
    Ghannoum, MA
    [J]. JOURNAL OF BACTERIOLOGY, 2001, 183 (18) : 5385 - 5394
  • [5] Clinical pharmacology of antifungal agents in pediatric patients
    Chiou, Christine C.
    Walsh, Thomas J.
    Groll, Andreas H.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (15) : 2465 - 2489
  • [6] CLSI, 2008, REF METH BROTH DIL A, V28
  • [7] Intravascular catheter-associated infections
    Crump, JA
    Collignon, PJ
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2000, 19 (01) : 1 - 8
  • [8] Candida biofilms and their role in infection
    Douglas, LJ
    [J]. TRENDS IN MICROBIOLOGY, 2003, 11 (01) : 30 - 36
  • [9] GRECO WR, 1995, PHARMACOL REV, V47, P331
  • [10] Posaconazole for paediatric patients: status of development and future perspectives
    Groll, Andreas H.
    Lehrnbecher, Thomas
    [J]. MYCOSES, 2008, 51 : 5 - 11